

Literatur

Kramer A, Meinke M, Patzelt A, Stope MB, Lademann J, Jacobs K. Perspektiven physikalischer Verfahren der Antiseptik und Desinfektion. HygMed 2020; 45(3): D39-D43

■ Literatur:

1. Kramer A, Assadian O. Wallhäußers Praxis der Sterilisation, Desinfektion, Antiseptik und Konservierung, Stuttgart: Thieme, 2008.
2. Below H, Assadian O, Baguhl R, Hildebrandt U, Jäger B, Meissner K, Leaper DJ, Kramer A. Measurements of chlorhexidine, p-chloroaniline, and p-chloronitrobenzene in saliva after mouth wash before and after operation with 0.2% chlorhexidine digluconate in maxillofacial surgery: a randomised controlled trial. *Brit J Oral Maxillofac Surg* 2017; 55 (2):150–155.
3. Cherednichenko G, Zhang R, Bannister RA, Timofeyev V, Li N, Fritsch EB, Feng W, Barrientos GC, Schebb NH, Hammock BD, Beam KG, Chiamvimonvat N, Pessah IN. Triclosan impairs excitation-contraction coupling and Ca²⁺ dynamics in striated muscle. *Proc Natl Acad Sci USA* 2012; 35:14158–63.
4. Clayton EM, Todd M, Dowd JB, Aiello AE. The impact of bisphenol a and triclosan on immune parameters in the U.S. Population, NHANES 2003–2006. *Environ Health Perspect* 2011;119(3):390–396.
5. Bertelsen RJ, Longnecker MP, Løvik M, Calafat AM, Carlsen KH, London SJ, Lødrup Carlsen KC. Triclosan exposure and allergic sensitization in Norwegian children. *Allergy* 2013;68(1): 84–91.
6. Syed A, Ghosh S, Love NG, Boles BR. Triclosan promotes *Staphylococcus aureus* nasal colonization. *mBio* 2014; 5(2): e01015-13.
7. Buth JM, Steen PO, Sueper C, Blumentritt D, Vikesland PJ, Arnold WA, McNeill K. Dioxin photoproducts of triclosan and its chlorinated derivatives in sediment cores. *Environ Sci Technol* 2010, 44: 4545–51.
8. Carey DE, McNamara PJ. The impact of triclosan on the spread of antibiotic resistance in the environment. *Front Microbiol* 2014; 5: 780.
9. Bragg R, Jansen A, Coetzee M, van der Westhuizen W, Boucher C. Bacterial resistance to Quaternary Ammonium Compounds (QAC) disinfectants. *Adv Exp Med Biol* 2014; 808:1–13.
10. Salas-Orozco M, Niño-Martínez N, Martínez-Castañón GA, Méndez FT, Jasso MEC, Ruiz F, mechanisms of resistance to silver nanoparticles in endodontic bacteria: A literature review. *J Nanomat* 2019, Article ID 7630316.
11. Cieplik F, Jakubovics NS, Buchalla W, Maisch T, Hellwig E, Al-Ahmad A. Resistance toward chlorhexidine in oral bacteria – is there cause for concern? *Front Microbiol* 2019;10:587.
12. Matthes R, Assadian O, Kramer A. Repeated applications of cold atmospheric pressure plasma does not induce resistance in *Staphylococcus aureus* embedded in biofilms. *GMS Hyg Infect Control* 2014;9(3):Doc17.
13. Dai T, Gupta A, Murray CK, Vrahas MS, Tegos GP, Hamblin MR. Blue light for infectious diseases: *Propionibacterium acnes*, *Helicobacter pylori*, and beyond. *Drug Resist Updat* 2012; 15 (4): 223–236.
14. Wang Y, Wang Y, Wang Y, Murray CK, Hamblin MR, Hooper DC, Dai T. Antimicrobial blue light inactivation of pathogenic microbes: state of the art. *Drug Resist Updat* 2017; 33–35: 1–22.
15. Tomb RM, Maclean M, Coia JE, Graham E, McDonald M, Atreya CD, MacGregor SJ, Anderson JG. New proof-of-concept in viral inactivation: virucidal efficacy of 405 nm light against feline calicivirus as a model for norovirus decontamination. *Food Environ Virol* 2017; 9(2):159–167.
16. McDonald R, MacGregor SJ, Anderson JG, Maclean M, Granta MH. Effect of 405-nm high-intensity narrow-spectrum light on fibroblast-populated collagen lattices: an in vitro model of wound healing. *J Biomed Optics* 2011; 16(4): 048003.
17. Hull NM, Herold WH, Linden KG. UV LED water disinfection: Validation and small system demonstration study. *AWWA Wat Sci* 2019;e1148.
18. Health Quality Ontario. Portable ultraviolet light surface-disinfecting devices for prevention of hospital-acquired infections: A health technology assessment. *Ont Health Technol Assess Ser* 2018; 18(1):1–73.
19. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018;66(7):e1-e48.
20. Buonanno M, Randers-Pehrson G, Bigelow AW, Trivedi S, Lowy FD, Spotnitz HM, Hammer SM, Brenner DJ. 207-nm UV light – a promising tool for safe low-cost reduction of surgical site infections. I: in vitro studies. *PLoS ONE* 2013; 8(19): e76968.
21. Saadati S. Study of ultraviolet C light penetration and damage in skin. Columbia Univ/Univ Gothenburg, 2016: https://radfys.gu.se/digitalAssets/1616/1616169_study-of-ultraviolet-c-light-penetration-and-damage-in-skin.pdf

22. Narita K, Asano K, Morimoto Y, Igarashi T, Hamblin MR, Dai T, Nakane A. Disinfection and healing effects of 222-nm UVC light on methicillin-resistant *Staphylococcus aureus* infection in mouse wounds. *J Photochem Photobiol B* 2018;178:10–18.
23. Narita K, Asano K, Morimoto Y, Igarashi T, Nakane A. Chronic irradiation with 222-nm UVC light induces neither DNA damage nor epidermal lesions in mouse skin, even at high doses. *PLoS One* 2018;13(7):e0201259.
24. Ponnaiya B, Buonanno M, Welch D, Shuryak I, Randers-Pehrson G, Brenner DJ. Far-UVC light prevents MRSA infection of superficial wounds in vivo. *PLOS ONE* 2018; 13(2): e0192053.
25. Hübner NO, Wander K, Ryll S, Lindsedt G, Kramer A. Antibiotikafreie Sanierung von MRSA-positivem Personal. *GMS Krankenhaushyg Interdisziplinär* 2009;4(2):Doc04.
26. Daeschlein G. Antimicrobial Activity of Plasma. In: Metelmann HR, von Woedtke, T, Weltmann KD (Eds) *Comprehensive Clinical Plasma Medicine*; Cham: Springer, 2018; 113–125.
27. Langner I, Kramer A, Matthes R, Rebert F, Kohler C, Koban I, Hübner NO, Kohlmann T, Patrzyk M. Inhibition of microbial growth by cold atmospheric plasma compared with the antiseptics chlorhexidine digluconate, octenidine dihydrochloride, and polyhexanide. *Plasma Proc Polymers* 2019; 16 (9):1–9.
28. Matthes R, Bender C, Schlüter R, Koban I, Bussiahn R, Reuter S, et al. Antimicrobial efficacy of two surface barrier discharges with air plasma against in vitro biofilms. *PLoS One* 2013; 8(7): e70462.
29. Abu-Bakr HA, Williams P, Gangal U, Youssef MM, El-Sohaimy SA, Brugge-man PJ, Goyal SM. Virucidal effect of cold atmospheric gaseous plasma on feline calicivirus, a surrogate for human norovirus. *Appl Environ Microbiol* 2015;81(11): 3612–22.
30. Bender C, Kramer A. Efficacy of Tissue Tolerable Plasma (TTP) against *Ixodes ricinus*. *GMS Hyg Infect Control*. 2014; 9(1): Doc04.
31. Kramer A, Schauer F, Papke R, Beke-schus S. Plasma Application for Hygienic Purposes in Medicine, Industry, and Biotechnology: Update 2017. In: Metelmann HR, von Woedtke, T, Weltmann KD (Eds) *Comprehensive Clinical Plasma Medicine*; Cham: Springer, 2018; 253–281.
32. Kramer A, Lademann J, Bender C, Sckell A, Hartmann B, Münch S, Hinz P, Ekkernkamp A, Matthes R, Koban I, Partecke I, Heidecke CD, Masur K, Reuter S, Weltmann KD, Koch S, Assadian O. Suitability of tissue tolerable plasmas (TTP) for the management of chronic wounds. *Clin Plasma Med* 2013;1(1):11–18.
33. Bender C, Matthes R, Kindel E, Kramer A, Lademann J, Weltmann KD, Eisenbeiß W, Hübner NH. The irritation potential of nonthermal atmospheric pressure plasma in the HET-CAM. *Plasma Proc Polymers* 2010; 7 (3–4): 318–326.
34. Bender C, Partecke LI, Kindel E, Döring F, Lademann J, Heidecke CD, Kramer A, Hübner NO. The modified HET-CAM as a model for the assessment of the inflammatory response to tissue tolerable plasma. *Toxicol in vitro* 2011; 25: 530–537.
35. Bender C, Kramer A. Behandlung von Wundheilungsstörungen beim Haustier mit kaltem Atmosphärendruckplasma. *Tierärztl Umschau* 2016; 71: 262–268.
36. Assadian O, Ousey KJ, Daeschlein G, Kramer A, Parker C, Tanner J, Leaper DJ. Effects and safety of atmospheric low-temperature plasma on bacterial reduction in chronic wounds and wound size reduction: A systematic review and meta-analysis. *Int Wound J* 2019;16(1): 103–111.
37. Bender C, Hübner NO, Weltmann KD, Scharf C, Kramer A. Tissue tolerable plasma and polyhexanide: Are synergistic effects possible to promote healing of chronic wounds? In vivo and in vitro results. In: Machala Z, Hensel K, Akishev Y (eds) *Plasma for Bio-Decontamination, Medicine and Food Security*; NATO Science for Peace and Security Series – A: Chemistry and Biology, Springer Nature Switzerland, 2011; 312–334.
38. Ulmer M, Lademann J, Patzelt A, Knorr F, Kramer A, Koburger T, Assadian O, Daeschlein G, Lange-Asschenfeldt B. New strategies for preoperative skin antiseptics. *Skin Pharmacol Physiol* 2014; 27(6):283–292.
39. Kramer A, Conway BR, Meissner K, Scholz F, Rauch BH, Moroder A, Ehlers A, Meixner AJ, Heidecke CD, Partecke LI, Kietzmann M, Assadian O. Cold atmospheric pressure plasma for treatment of chronic wounds: drug or medical device? *J Wound Care* 2017;26(8):470–475.
40. Lademann J, Richter H, Meinke MC, Patzelt A, Kramer A, Hinz P, Weltmann KD, Hartmann B, Koch S. Drug delivery through the skin barrier enhanced by treatment with tissue-tolerable plasma. *Exp Derm* 2011; 20(6):488–490.
41. Lademann J, Richter H, Kramer A, Lademann O. Enhancement of the Penetration of Topically Applied Substances by Tissue-Tolerable Plasma. In: Metelmann HR, von Woedtke, T, Weltmann KD (eds) *Comprehensive Clinical Plasma Medicine*; Cham: Springer, 2016; 441–447.
42. Lange-Asschenfeldt B, Marenbach D, Lang C, Patzelt A, Ulrich M, Maltusch A, Terhorst D, Stockfleth E, Sterry W, Lademann J. Distribution of bacteria in the epidermal layers and hair follicles of the human skin. *Skin Pharmacol Physiol* 2011; 24: 305–311.
43. Kadler BK, Mehta SS, Funk L. *Propionibacterium acnes* infection after shoulder surgery. *Int J Shoulder Surg* 2015;9: 139–144.
44. Tande AJ, Patel R. Prosthetic joint infection. *Clin Microbiol Rev* 2014; 27(2): 302–345.
45. Gharamti A, Kanafani ZA. Vascular graft infections. An update. *Infect Dis Clin North Am* 2018;32(4): 789–809.